Wednesday, 25th of July 2012 |
L. Morris1, R. Posada1, C. Hickman2, D. Latner2, T. Singh3, A. Rautenberg3, J. Jao4, W. Bellini2, R. Sperling3
1Mount Sinai School of Medicine, Division of Pediatric Infectious Disease, New York, United States, 2Centers for Disease Control & Prevention, Division of Viral Diseases, Atlanta, United States, 3Mount Sinai School of Medicine, Department of OB/Gyn, New York, United States, 4Mount Sinai School of Medicine, Division of Infectious Disease, New York, United StatesAlso accessible at http://pag.aids2012.org/abstracts.aspx?aid=14088
Background: Many youth with perinatally acquired HIV (PAH) exhibit poor immune responses to vaccinations, including measles, mumps and rubella (MMR). This has worldwide public health implications, particularly in areas with high prevalence of HIV and measles. The objective of this pilot study was to determine the prevalence of measles immunity among individuals with PAH and prior MMR vaccination.
Methods: Individuals with PAH >13 years old, receiving care at Mount Sinai Hospital (MSH), New York with prior MMR vaccination were enrolled. Measles IgG titers were determined at MSH via commercially available ELISA and at the Centers for Disease Control and Prevention, Atlanta by plaque reduction neutralization (PRN) assay. Measles immunity was defined as IgG titers >120mIU by PRN assay. Medical records were reviewed for demographics and pertinent clinical data. P-values were calculated using Wilcoxon test, Chi-square or Fisher's exact test as appropriate.
Results: Based on PRN assay, only 6/34 (17.6%) subjects were measles immune. Measles immune subjects were younger [median age 14.5 vs. 19 years (p=0.01)]. Differences in gender and race/ethnicity were not statistically significant between immune and non-immune groups [65% vs. 50% female (p=0.648) and 79% vs. 67% Black or Hispanic (p=0.802) respectively].
|
Measles Non-Immune |
Measles Immune |
p-value |
Age, years (Median) (IQR) |
19 (17-20) |
14.5 (13-18) |
0.01 |
Female, No. (%) |
19 (65%) |
3 (50%) |
0.648 |
Race/Ethnicity, No. (%) |
|
|
0.802 |
White |
1 (4%) |
0 (0%) |
|
African American |
7 (24%) |
1 (17%) |
|
Hispanic |
16 (55%) |
3 (50%) |
|
Other |
5 (17%) |
2 (33%) |
|
Measles Non-Immune |
Measles Immune |
p-value |
18 (62%) |
1 (17%) |
0.07 |
143 (23-231) |
299 (34-442) |
0.175 |
14 (3-25) |
25 (7-41) |
0.227 |
3.74 (3.18-4.3) |
2.79 (1.22-4.36) |
0.159 |
2 (1-4) |
2 (2-3) |
0.618 |
12 (11-18) |
13.5 (11-15) |
0.873 |
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
41199840 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |